Clinical efficacy and safety of Picamilon in patients with progressive chronic cerebral ischemia
Observational study · 2024
- What was studied
- 50 stage II patients (5 men, 45 women); 70-day active treatment and 45-day follow-up
- Main finding
- In an uncontrolled 50-person stage II cohort, cognition and sleep questionnaire scores improved during treatment and follow-up.
MoCA cognitive score · 20.9 → 24.6 → 25.9 points · Baseline → end of treatment → delayed follow-up · p<0.0001 and p=0.0006 as reported
Reported findings and study design
In an uncontrolled 50-person stage II cohort, cognition and sleep questionnaire scores improved during treatment and follow-up.
50 patients; 10 days intravenous treatment followed by 60 days oral treatment; final follow-up 1.5 months later.
Population or model 50 stage II patients (5 men, 45 women); 70-day active treatment and 45-day follow-up
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MoCA cognitive score | 20.9 → 24.6 → 25.9 points | Baseline → end of treatment → delayed follow-up · p<0.0001 and p=0.0006 as reported |
| Sleep normalization | 55% → 81% | End of treatment → delayed follow-up; questionnaire-defined · p<0.0001 and p=0.0025 |
| Fedin neurological score | 17.4 ± 9.34 → 8.06 ± 6.84 → 5.31 ± 5.71 points | Baseline → visit 2 → visit 3 · p<0.0001 and p=0.0002 |
| Neurological improvement | 84% | Within treated cohort |
| Autonomic findings | 38% normalized; 60% had reduced symptom severity | Separate response categories · p=0.0001 as reported |
| Reported tolerability | 98% | Uncontrolled cohort; not a placebo safety comparison |
No untreated comparator was included. Questionnaire sleep changes do not describe deep or REM sleep. Clinical-event prevention is not established by these scale and vascular-marker changes.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- Uncontrolled treatment cohort; expectation, repeated testing and concomitant care can affect outcomes.
- Questionnaire improvement is not evidence about wearable sleep stages.
- Strong similarities to the 2025 stage II group warrant overlap checks before any pooling.
Related publications may describe some of the same participants or experiments.
Source details
Publisher HTML article
Original publisher abstract and selected HTML results checked; patient-series overlap remains unresolved
Sources checked
Citation
Danilov AB, Shindryaeva NN, Borodulina IV, Lunegov TD, Kristeleva DA. Clinical efficacy and safety of Picamilon in patients with progressive chronic cerebral ischemia Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 124(8). PMID 39269299
Study source ↗ · DOI 10.17116/jnevro202412408171 · Bibliography entry · Link to this summary